Advertisement

Topics

HCC drops beyond five years of entecavir / tenofovir Tx for hepatitis B

13:17 EDT 21 Jun 2017 | Medical Xpress

(HealthDay)—For Caucasian patients with chronic hepatitis B (CHB), the incidence of hepatocellular carcinoma (HCC) decreases beyond year five of entecavir/tenofovir therapy, particularly in those with compensated cirrhosis, according to a study published online June 16 in Hepatology.

Original Article: HCC drops beyond five years of entecavir / tenofovir Tx for hepatitis B

NEXT ARTICLE

More From BioPortfolio on "HCC drops beyond five years of entecavir / tenofovir Tx for hepatitis B"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...